Daniel A. Ermann
( out of 102 reviews )

Daniel A. Ermann, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-0236

  • Daniel Ermann, MD joined the Division of Hematology/Hematologic Malignancies as an Associate Professor in 2023 after completing his Hematology/Oncology fellowship at the Huntsman Cancer Institute of the University of Utah. Dr. Ermann’s clinical expertise is focused on patients with chronic lymphocytic leukemia (CLL) and other forms of non-Hodgkin lymphoma (NHL). He is passionate about working towards a cure for these malignancies. Dr. Ermann is currently the physician lead of the CLL clinical trials program at Huntsman Cancer Institute. His primary research interests include; implementing new targeted therapies for patients with CLL and lymphoma, evaluating novel treatment combinations, and developing supportive clinical trials for the complications of CLL. Dr. Ermann's research focus is to develop and implement ground-breaking clinical trials that can lead to new standards-of-care/treatments for CLL and NHL patients. Dr. Ermann is the principal investigator on more than 8 ongoing clinical trials at Huntsman Cancer Institute and is involved in the national SWOG CLL Working Group which develops and opens important trials for CLL patients around the world. He is also focused on evaluating and improving the outcomes and research, on current standards-of-care across the spectrum of lymphoma management. Dr. Ermann is originally from Pennsylvania where he graduated from the University of Pittsburgh. He earned his medical degree from St. George’s University prior to completing his Internal Medicine residency training at Creighton University in Omaha, Nebraska.

    For questions regarding Dr. Ermann's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at (801) 585-6906.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Patient Rating

    5.0 /5
    ( out of 102 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    November 20, 2024
    HUNTSMAN CANCER CENTER

    Iwouldnt want any other Dr. For my care.

    November 09, 2024
    HUNTSMAN CANCER CENTER

    My wife and I were both impressed and grateful for the personal time Dr Ermann spent with us discussing my treatment options in a very easy to understand manner and answered our every question without making us feel hurried on unheard. By the end of our discussion, we were all in agreement that the best treatment plan for me had been identified, selected, and completely understood.

    November 08, 2024
    HUNTSMAN CANCER CENTER

    Dr Ermann is a very caring and knowledgeable doctor. I am very comfortable in his care

    November 03, 2024
    HUNTSMAN CANCER CENTER

    Very smart doctor

    October 29, 2024
    HUNTSMAN CANCER CENTER

    Fantastic doctor. Explained everything very clearly and listened to our concerns.

    October 06, 2024
    HUNTSMAN CANCER CENTER

    My first visit with Dr Ermann. He was very nice, informative and knowledgeable about my condition.

    October 02, 2024
    HUNTSMAN CANCER CENTER

    Dr. Ermann showed genuine concern for my well being and clearly answered all my questions.

    September 29, 2024
    HUNTSMAN CANCER CENTER

    When I first saw the doctor he was very polite. He had very good aura about him. I felt comfortable around him. He was very knowledgeable, intelligent, clean and he allowed me to speak and ask questions and he answered them to the way I could understand him. Thank you, Dr. Daniel Arthur erdman

    September 26, 2024
    HUNTSMAN CANCER CENTER

    Dr Ermann explained things to me in a way I could understand. I felt listened to and validated.

    See More Patient Comments

  • Daniel Ermann, MD joined the Division of Hematology/Hematologic Malignancies as an Associate Professor in 2023 after completing his Hematology/Oncology fellowship at the Huntsman Cancer Institute of the University of Utah. Dr. Ermann’s clinical expertise is focused on patients with chronic lymphocytic leukemia (CLL) and other forms of non-Hodgkin lymphoma (NHL). He is passionate about working towards a cure for these malignancies. Dr. Ermann is currently the physician lead of the CLL clinical trials program at Huntsman Cancer Institute. His primary research interests include; implementing new targeted therapies for patients with CLL and lymphoma, evaluating novel treatment combinations, and developing supportive clinical trials for the complications of CLL. Dr. Ermann's research focus is to develop and implement ground-breaking clinical trials that can lead to new standards-of-care/treatments for CLL and NHL patients. Dr. Ermann is the principal investigator on more than 8 ongoing clinical trials at Huntsman Cancer Institute and is involved in the national SWOG CLL Working Group which develops and opens important trials for CLL patients around the world. He is also focused on evaluating and improving the outcomes and research, on current standards-of-care across the spectrum of lymphoma management. Dr. Ermann is originally from Pennsylvania where he graduated from the University of Pittsburgh. He earned his medical degree from St. George’s University prior to completing his Internal Medicine residency training at Creighton University in Omaha, Nebraska.

    For questions regarding Dr. Ermann's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at (801) 585-6906.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Education history

    Fellowship Hematology/Oncology - Huntsman Cancer institute, University of Utah School of Medicine Administrative Chief Fellow
    Fellowship Hematology/Oncology - Huntsman Cancer institute, University of Utah School of Medicine Fellow
    Residency Internal Medicine - Creighton University School of Medicine Chief Resident
    Residency Internal Medicine - Creighton University School of Medicine Resident
    Professional Medical Medicine - St. George's University School of Medicine M.D.
    Undergraduate Major: Biology; Minor: Chemistry - University of Pittsburgh B.S.

    Selected Publications

    Journal Article

    1. Soumerai JD, Barrientos JC, Ahn IE, Coombs CC, Gladstone DE, Hoffmann MS, Kittai AS, Jacobs RW, Lipsky A, Patel K, Rhodes JM, Skarbnik AP, Thompson MC, Ermann DA, Reville PK, Shah HR, Brown JR, Stephens DM (2024). Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL. Blood Adv. (Read full article)
    2. Samples L, Voutsinas JM MPH, Fakhri B, Khajavian S, Spurgeon SE, Stephens DM, Skarbnik AP, Mato AR, Broome C, Gopal AK, Smith SD, Lynch RC, Rainey MA, Kim MS, Barrett-Campbell O, Hemond E, Tsang M, Ermann DA, Malakhov N, Rao D, Shakib-Azar M, Morrigan B, Chauhan A, Plate T, Gooley TA, Ryan K, Lansigan F, Hill BT, Pongas G, Parikh SA, Roeker LE, Allan JN, Cheng R, Ujjani C, Shadman M (2024). Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study. Blood Adv. (Read full article)
    3. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica, 108(11), 3025-3032. (Read full article)
    4. Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, Stephens DM, Hu B (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clin Lymphoma Myeloma Leuk, 24(2), 94-104.e6. (Read full article)
    5. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov DW (2022). Impact of academic medical center access on outcomes in multiple myeloma. Am J Hematol, 98(1), 41-48. (Read full article)
    6. Major A, Cliff ERS, Ermann DA, Durani U, Russler-Germain DA (2022). Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions. EJHaem, 3(3), 930-935. (Read full article)
    7. Ermann DA, Vardell VA, Kallam A, Silberstein PT, Armitage JO (2019). Academic Centers Compared With Nonacademic Centers for Patients With International Prognostic Index Risk-stratified Diffuse Large B-cell Lymphoma: A Survival Outcomes Analysis. Clin Lymphoma Myeloma Leuk, 20(4), e174-e183. (Read full article)
    8. Pierce TP, Ermann D, Scillia AJ, Festa A, Emami A, McInerney VK (2019). National Trends in Orthopaedic Surgery Resident Adult Case Logs. J Surg Educ, 76(3), 893-897. (Read full article)
    9. Vardell Noble V, Ermann DA, Griffin EK, Silberstein PT (2019). Primary Thyroid Lymphoma: An Analysis of the National Cancer Database. Cureus, 11(2), e4088. (Read full article)
    10. Ermann DA, Noble VV, Fazeel HM, Thomas B, Silberstein PT (2019). Presentation of a Rare Malignancy: Leiomyosarcoma of the Prostate. Fed Pract, 36(Suppl 1), S30-S33. (Read full article)

    Commentary

    1. Ermann DA, and Kittai AS (2024). Richter Transformation of Chronic Lymphocytic Leukemia Is a Challenging Clinical Scenario Requiring a Personalized Approach. ASCO Daily News. ASCO Daily News.

    Letter

    1. Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens DM (2024). T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments. [Letter to the editor]. Am J Hematol, 99(3), 494-496. (Read full article)
    2. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens DM (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. [Letter to the editor]. Am J Hematol, 98(7), E172-E174. (Read full article)

    Abstract

    1. Steven M Bair, Mayur Narkhede, Zachary AK Frosch, Elise A Chong, Daniel A Ermann, Iris Isufi, Farrukh T Awan, Julio C Chavez, Grace N Bosma, and Diana Abbott (2023). Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy [Abstract].
    2. Sanjal H Desai, Nuttavut Sumransub, Rich Evans, Marcus P Watkins, Reem Karmali, MD, Gaurav Goyal, Mitchell E Hughes, Arushi Khurana, Francisco J Hernandez-Ilizaliturri, Joanna Zurko, Ayesha Hassan, Haris Hatic, Imran A Nizamuddin, Andrew M Evens, Andrea Carolina Anampa-Guzmn, Yi Lin, MD, Iris Isufi, Mehdi Hamadani, Saurabh A Rajguru, Naveena Lall, Aung M Tun, Brian T Hill, Deborah M Stephens, Paolo F Caimi, Daniel A Ermann, Brad S Kahl, Daniel J Landsburg, and Grzegorz S Nowakowski (2023). Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy [Abstract].

  • News & Podcasts

    Huntsman Cancer Institute News

  • Clinical Trials